TVARDI THERAPEUTICS, INC. Cost of Revenue
TVARDI THERAPEUTICS, INC. (TVRD) reported Cost of Revenue of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-01.
Discontinued › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2022-03-01
- TVARDI THERAPEUTICS, INC. cost of goods and services sold for fiscal 2021 was $0.00.
| Period end | Cost of Goods and Services Sold 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |